Mucoadhesive TMC-coated solid lipid nanoparticles for oral co-delivery of docetaxel and curcumin: formulation optimization, in vitro characterization, and cytotoxic evaluation

Authors:

Abstract
Solid lipid nanoparticles (SLNs) coated with N-trimethyl chitosan (TMC) represent advanced strategy for oral drug delivery due to enhanced mucoadhesion and gastrointestinal stability. This study aimed to develop, characterize, and evaluate TMC-coated SLNs for the oral co-delivery of docetaxel (DTX) and curcumin (CUR). Main objectives of this study are enhancement of gastrointestinal stability, sustained drug release, and improvement of antitumor effects against breast cancer cells. TMC-modified SLNs were synthetized using a microemulsion and ultrasonication technique. Characterization of physicochemical properties (particle size, polydispersity index (PDI), zeta potential, encapsulation efficiency (EE%), morphological appearance (SEM)) and in vitro release behavior was performed. Moreover, the pH-dependent drug release mechanism and kinetic modeling of the release process were studied. Cytotoxicity was determined in MCF-7 breast cancer cells and normal MCF-10 A cells using the MTT assay. The optimized TMC-SLNs represent a spherical morphology with a mean particle size of 136.7 ± 6.4 nm, PDI of 0.315 ± 0.037, and a zeta potential of - 10.9 mV. The formulation achieved high EE% (> 97%) for both drugs. Gastric burst release was effectively decreased to less than 2%, mainly because of the protonation of amine groups of TMC at acidic conditions, thus increasing stability in the gastrointestinal tract. The release kinetics followed the Korsmeyer-Peppas model (97%), indicating a non-Fickian diffusion mechanism governed by polymer relaxation. The system showed sustained and pH-triggered drug release, with a cumulative drug release profile reaching 50.4% of DTX and 58.6% of CUR release over 96 h. In vitro cytotoxicity confirmed the increased cytotoxic effect of TMC-SLNs compared to free drugs and blank SLNs. The effect could be related to their better mucoadhesive properties and intracellular internalization. Moreover, no toxic effects were observed towards normal MCF-10 A cells. The developed TMC-coated SLNs provide a robust platform for the oral co-delivery of DTX and CUR. The formulation offers enhanced stability, controlled release kinetics, and therapeutic potential, that support its further investigation for breast cancer treatment.

This publication has 59 references indexed in Scilit: